Table 2 Diabetes therapy in patients with LADA and T2D.
Treatment | LADA | T2D | χ2, p | t, p | ||
|---|---|---|---|---|---|---|
n = 59, % | Dose | n = 318, % | Dose | |||
Insulin | 47 (79.7%) | 37.3 ± 18.7 IU/day | 199 (62.6%) | 39.8 ± 23.7 IU/day | 6.4, < 0.01 | − 0.7, 0.5 |
Short-Acting insulin | 12 (25.5%) | 15.0 ± 6.2 IU/day | 89 (44.7%) | 20.2 ± 14.6 IU/day | 5.8, 0.01 | − 2.2, 0.03 |
Intermediate-Acting insulin | 18 (38.3%) | 35.3 ± 11.4 IU/day | 80 (40.2%) | 35.0 ± 14.7 IU/day | 0.1, 0.47 | 0.1, 0.94 |
Long-Acting insulin | 33 (70.2%) | 28.4 ± 9.8 IU/day | 102 (51.3%) | 26.4 ± 11.7 IU/day | 5.5, 0.01 | 0.9, 0.36 |
Metformin | 57 (96.6%) | 1828.1 ± 541.2 mg/day | 269 (84.6%) | 1770.4 ± 564.3 mg/day | 6.2, < 0.01 | 0.7, 0.48 |
Glibenclamide | 28 (47.5%) | 9.6 ± 3.3 mg/day | 134 (42.1%) | 11.0 ± 4.1 mg/day | 0.6, 0.27 | − 1.7, 0.09 |
Linagliptin | 7 (11.9%) | 5.7 ± 1.9 mg/day | 88 (27.7%) | 5.4 ± 1.6 mg/day | 6.6, < 0.01 | 0.5, 0.61 |
